{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:12:56Z","timestamp":1784074376981,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11060-025-05139-1","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T10:13:00Z","timestamp":1753092780000},"page":"367-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024"],"prefix":"10.1007","volume":"175","author":[{"given":"Megan","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa G.","family":"Arbuiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Materi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej D.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny Suk","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Sahebjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Kamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Kleinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordina","family":"Rincon-Torroella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"5139_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit Cancer surveillance system. J Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"5139_CR2","doi-asserted-by":"publisher","first-page":"vdad015","DOI":"10.1093\/noajnl\/vdad015","volume":"5","author":"M Parker","year":"2023","unstructured":"Parker M, Jiang K, Rincon-Torroella J et al (2023) Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study. Neurooncol Adv 5:vdad015. https:\/\/doi.org\/10.1093\/noajnl\/vdad015","journal-title":"Neurooncol Adv"},{"key":"5139_CR3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","volume":"6","author":"JB S\u00f8rensen","year":"1988","unstructured":"S\u00f8rensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6:1474\u20131480. https:\/\/doi.org\/10.1200\/JCO.1988.6.9.1474","journal-title":"J Clin Oncol"},{"key":"5139_CR4","doi-asserted-by":"publisher","unstructured":"Bar J, Urban D, Amit U et al (2021) Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. J Oncol 2021:7836264. https:\/\/doi.org\/10.1155\/2021\/7836264","DOI":"10.1155\/2021\/7836264"},{"key":"5139_CR5","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K et al (2017) Using the National Cancer database for outcomes research: A review. JAMA Oncol 3:1722\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"5139_CR6","doi-asserted-by":"publisher","unstructured":"Newman SJ, Hansen HH (1974) Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33:492\u2013496. https:\/\/doi.org\/10.1002\/1097-0142(197402)33:2%3C492::aid-cncr2820330225%3E3.0.co;2-o","DOI":"10.1002\/1097-0142(197402)33:2%3C492::aid-cncr2820330225%3E3.0.co;2-o"},{"key":"5139_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/bjc.1956.47","volume":"10","author":"S Galluzzi","year":"1956","unstructured":"Galluzzi S, Payne PM (1956) Brain metastases from primary bronchial carcinoma: a statistical study of 741 necropsies. Br J Cancer 10:408\u2013414. https:\/\/doi.org\/10.1038\/bjc.1956.47","journal-title":"Br J Cancer"},{"key":"5139_CR8","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2023.5.FOCUS23212","volume":"55","author":"K Jiang","year":"2023","unstructured":"Jiang K, Parker M, Materi J et al (2023) Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study. Neurosurg Focus 55:E3. https:\/\/doi.org\/10.3171\/2023.5.FOCUS23212","journal-title":"Neurosurg Focus"},{"key":"5139_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC Cancer staging manual: continuing to build a Bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67:93\u201399. https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"5139_CR10","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1093\/oncolo\/oyad170","volume":"28","author":"EN Smyth","year":"2023","unstructured":"Smyth EN, John J, Tiu RV et al (2023) Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the united States. Oncologist 28:e1075\u2013e1091. https:\/\/doi.org\/10.1093\/oncolo\/oyad170","journal-title":"Oncologist"},{"key":"5139_CR11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/cncr.30000","volume":"122","author":"PH Goncalves","year":"2016","unstructured":"Goncalves PH, Peterson SL, Vigneau FD et al (2016) Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the metropolitan Detroit surveillance, epidemiology, and end results (SEER) data. Cancer 122:1921\u20131927. https:\/\/doi.org\/10.1002\/cncr.30000","journal-title":"Cancer"},{"key":"5139_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","volume":"75","author":"IT Gavrilovic","year":"2005","unstructured":"Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5\u201314. https:\/\/doi.org\/10.1007\/s11060-004-8093-6","journal-title":"J Neurooncol"},{"key":"5139_CR13","unstructured":"National Comprehensive Cancer Network\u00ae (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Non-Small Cell Lung Cancer Version 2.2024"},{"key":"5139_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00330-021-08215-y","volume":"32","author":"S Park","year":"2022","unstructured":"Park S, Lee SM, Ahn Y et al (2022) Identification of predictors for brain metastasis in newly diagnosed non-small cell lung cancer: a single-center cohort study. Eur Radiol 32:990\u20131001. https:\/\/doi.org\/10.1007\/s00330-021-08215-y","journal-title":"Eur Radiol"},{"key":"5139_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/0284186x.2018.1564841","volume":"58","author":"RE Wegner","year":"2019","unstructured":"Wegner RE, Hasan S, Williamson RW et al (2019) Management of brain metastases from large cell neuroendocrine carcinoma of the lung: improved outcomes with radiosurgery. Acta Oncol 58:499\u2013504. https:\/\/doi.org\/10.1080\/0284186x.2018.1564841","journal-title":"Acta Oncol"},{"key":"5139_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s1556-0864(15)31569-0","volume":"1","author":"AA Shi","year":"2006","unstructured":"Shi AA, Digumarthy SR, Temel JS et al (2006) Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol 1:205\u2013210. https:\/\/doi.org\/10.1016\/s1556-0864(15)31569-0","journal-title":"J Thorac Oncol"},{"key":"5139_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.6004\/jnccn.2010.0056","volume":"8","author":"DS Ettinger","year":"2010","unstructured":"Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740\u2013801. https:\/\/doi.org\/10.6004\/jnccn.2010.0056","journal-title":"J Natl Compr Canc Netw"},{"key":"5139_CR18","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T (2019) Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 8:S298\u2013S307. https:\/\/doi.org\/10.21037\/tlcr.2019.05.15","journal-title":"Transl Lung Cancer Res"},{"key":"5139_CR19","doi-asserted-by":"publisher","first-page":"109627","DOI":"10.1016\/j.radonc.2023.109627","volume":"183","author":"H Zeng","year":"2023","unstructured":"Zeng H, Hendriks LEL, Witlox WJA et al (2023) Risk factors for cognitive impairment in radically treated stage III NSCLC: secondary findings of the NVALT-11 study. Radiother Oncol 183:109627. https:\/\/doi.org\/10.1016\/j.radonc.2023.109627","journal-title":"Radiother Oncol"},{"key":"5139_CR20","doi-asserted-by":"publisher","first-page":"S1874","DOI":"10.1016\/j.jtho.2017.09.616","volume":"12","author":"D De Ruysscher","year":"2017","unstructured":"De Ruysscher D, Dingemans A, Praag J et al (2017) Toxicity results from the randomized phase III NVALT-11 study of prophylactic cranial irradiation vs. observation in stage III NSCLC. J Thorac Oncol 12:S1874\u2013S1875","journal-title":"J Thorac Oncol"},{"key":"5139_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","volume":"303","author":"R Timmerman","year":"2010","unstructured":"Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070\u20131076. https:\/\/doi.org\/10.1001\/jama.2010.261","journal-title":"JAMA"},{"key":"5139_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijrobp.2004.06.260","volume":"61","author":"J Bradley","year":"2005","unstructured":"Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318\u2013328. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.06.260","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5139_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijrobp.2005.02.010","volume":"63","author":"F-M Kong","year":"2005","unstructured":"Kong F-M, Ten Haken RK, Schipper MJ et al (2005) High-dose radiation improved local tumor control and overall survival in patients with inoperable\/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63:324\u2013333. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.02.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5139_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","volume":"68","author":"A Bearz","year":"2010","unstructured":"Bearz A, Garassino I, Tiseo M et al (2010) Activity of pemetrexed on brain metastases from Non-Small cell lung Cancer. Lung Cancer 68:264\u2013268. https:\/\/doi.org\/10.1016\/j.lungcan.2009.06.018","journal-title":"Lung Cancer"},{"key":"5139_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316:401\u2013409. https:\/\/doi.org\/10.1001\/jama.2016.9839","journal-title":"JAMA"},{"key":"5139_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ijrobp.2019.03.052","volume":"104","author":"RT Hughes","year":"2019","unstructured":"Hughes RT, Masters AH, McTyre ER et al (2019) Initial SRS for patients with 5 to 15 brain metastases: results of a Multi-Institutional experience. Int J Radiat Oncol Biol Phys 104:1091\u20131098. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.052","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5139_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2008.04.013","volume":"63","author":"J S\u00e1nchez de Cos","year":"2009","unstructured":"S\u00e1nchez de Cos J, Sojo Gonz\u00e1lez MA, Montero MV et al (2009) Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 63:140\u2013145. https:\/\/doi.org\/10.1016\/j.lungcan.2008.04.013","journal-title":"Lung Cancer"},{"key":"5139_CR28","doi-asserted-by":"publisher","unstructured":"Alessi JV, Ricciuti B, Jim\u00e9nez-Aguilar E et al (2020) Outcomes to first-line pembrolizumab in patients with PD-L1-high (\u2265\u200950%) non-small cell lung cancer and a poor performance status. J Immunother Cancer 8. https:\/\/doi.org\/10.1136\/jitc-2020-001007","DOI":"10.1136\/jitc-2020-001007"},{"key":"5139_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 21:655\u2013663. https:\/\/doi.org\/10.1016\/S1470-2045(20)30111-X","journal-title":"Lancet Oncol"},{"key":"5139_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","volume":"22","author":"L Sun","year":"2021","unstructured":"Sun L, Davis CW, Hwang WT et al (2021) Outcomes in patients with Non-small-cell lung Cancer with brain metastases treated with Pembrolizumab-based therapy. Clin Lung Cancer 22:58\u201366e3. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.017","journal-title":"Clin Lung Cancer"},{"key":"5139_CR31","doi-asserted-by":"publisher","first-page":"v604","DOI":"10.1093\/annonc\/mdz260.004","volume":"30","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Herbst RS, Castro G et al (2019) Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1\u00e2\u20acpositive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, -010, -024, and\u2013\u2009042. Ann Oncol 30:v604\u2013v606. https:\/\/doi.org\/10.1093\/annonc\/mdz260.004","journal-title":"Ann Oncol"},{"key":"5139_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-024-04562-0","volume":"166","author":"I Averbuch","year":"2024","unstructured":"Averbuch I, Tschernichovsky R, Yust-Katz S et al (2024) Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment. J Neurooncol 166:461\u2013469. https:\/\/doi.org\/10.1007\/s11060-024-04562-0","journal-title":"J Neurooncol"},{"key":"5139_CR33","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"Y-L Wu","year":"2018","unstructured":"Wu Y-L, Ahn M-J, Garassino MC et al (2018) CNS efficacy of osimertinib in patients with T790M-Positive advanced Non-Small-Cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 36:2702\u20132709. https:\/\/doi.org\/10.1200\/JCO.2018.77.9363","journal-title":"J Clin Oncol"},{"key":"5139_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus Crizotinib in untreated ALK-Positive Non\u2013Small-Cell lung Cancer. N Engl J Med 377:829\u2013838. https:\/\/doi.org\/10.1056\/NEJMoa1704795","journal-title":"N Engl J Med"},{"key":"5139_CR35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM et al (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056\u20131064. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.478","journal-title":"Ann Oncol"},{"key":"5139_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s12094-013-1008-2","volume":"15","author":"Q Xu","year":"2013","unstructured":"Xu Q, Wang Y, Liu H et al (2013) Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis. Clin Transl Oncol 15:802\u2013809. https:\/\/doi.org\/10.1007\/s12094-013-1008-2","journal-title":"Clin Transl Oncol"},{"key":"5139_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10585-015-9699-0","volume":"32","author":"PM Putora","year":"2015","unstructured":"Putora PM, Ess S, Panje C et al (2015) Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 32:143\u2013149. https:\/\/doi.org\/10.1007\/s10585-015-9699-0","journal-title":"Clin Exp Metastasis"},{"key":"5139_CR38","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: summary report on the updated Diagnosis-Specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38:3773\u20133784. https:\/\/doi.org\/10.1200\/JCO.20.01255","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05139-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:22:04Z","timestamp":1757262124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05139-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5139"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05139-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by the Institutional Review Board and Johns Hopkins University. Consent to participate was waived by the Institutional Review Board and Johns Hopkins University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.B.: is a consultant for Depuy-Synthes, Bionaut Labs, Galectin Therapeutics, Haystack Oncology, and Privo Technologies. C.B. is a co-founder of OrisDx and Belay Diagnostics. K.J.R.: Research funding from Accuray, Canon, Elekta AB, icotec; travel expenses from Elekta AB, Accuray, icotec, Brainlab; patent under development with Canon for radiogenomics; data safety monitoring board for BioMimetix.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was presented as a poster presentation at the Congress of Neurological Surgeons 2024 Annual Meeting in Houston, Texas.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}}]}}